Journal of Clinical Epidemiology
Volume 51, Issue 2 , Pages 69-79, February 1998

A Study in Contrasts: Eligibility Criteria in a Twenty-Year Sample of NSABP and POG Clinical Trials

  • Abraham Fuks

      Affiliations

    • Faculty of Medicine, McGill University, Montreal, Quebec, Canada
    • Clinical Trials Research Group, McGill University, Montreal, Quebec, Canada
  • ,
  • Charles Weijer

      Affiliations

    • Mount Sinai Hospital, Toronto, Ontario, Canada
    • University of Toronto, Toronto, Ontario, Canada
    • Corresponding Author InformationCharles Weijer, M.D., Ph.D., Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario, Canada M5G 1X5
  • ,
  • Benjamin Freedman

      Affiliations

    • Biomedical Ethics Unit, McGill University, Montreal, Quebec, Canada
    • Clinical Trials Research Group, McGill University, Montreal, Quebec, Canada
  • ,
  • Stanley Shapiro

      Affiliations

    • Faculty of Medicine, McGill University, Montreal, Quebec, Canada
    • Clinical Trials Research Group, McGill University, Montreal, Quebec, Canada
  • ,
  • Myriam Skrutkowska

      Affiliations

    • Clinical Trials Research Group, McGill University, Montreal, Quebec, Canada
  • ,
  • Amina Riaz

      Affiliations

    • Clinical Trials Research Group, McGill University, Montreal, Quebec, Canada

Accepted 7 October 1997.

Abstract 

We studied changes in eligibility criteria—the largest impediment to patient accrual—in two samples of clinical trials. Trials from the NSABP (National Surgical Adjuvant Breast and Bowel Program) and POG (Pediatric Oncology Group) were analyzed. After eliminating duplications, the criteria in each protocol were enumerated and classified according to a novel schema. NSABP trials contained significantly more criteria than POG trials, and added precision criteria (making study populations homogeneous) at a faster rate than POG studies. The difference between NSABP studies (explanatory trials) and POG studies (pragmatic trials) suggest that large numbers of eligibility criteria are not necessary for quality studies. We recommend that: (1) the inclusion/exclusion criteria distinction be abandoned; (2) eligibility criteria be explicitly justified; (3) the need for each criterion be assessed when new trials are planned; (4) criteria in phase III trials restricting patient accrual be minimized; and (5) further research be done to assess the impact of criteria on generalizability.

Keywords:  Clinical trials, eligibility determination, patient participation, neoplasms/treatment, ethics

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0895-4356(97)00240-0

Journal of Clinical Epidemiology
Volume 51, Issue 2 , Pages 69-79, February 1998